Spectrum and its subsidiaries have five FDA-approved oncology/hematology products available through our Commercial Team of regional oncology specialists. For more information on the Spectrum's marketed products, please click on the respective product web site links below.
FUSILEV, a folate analog, is available commercially in vials for injection as freeze-dried powder.
In 2011, Spectrum Pharmaceuticals sought multiple supply sources for FUSILEV, to offset any demand increase. Currently, Spectrum is able to meet all supply requirements.
FUSILEV is a folate analog indicated for:
Limitations of Use
• FUSILEV is not approved for pernicious anemia and megaloblastic anemias. Improper use may cause a hematologic remission while neurologic manifestations continue to progress.
Important Safety Information for FUSILEV
Indications and Usage for FOLOTYN
FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
The indication for FOLOTYN is based on overall response rate. Clinical benefit such as improvement in progression free survival or overall survival has not been demonstrated.
FOLOTYN was the first chemotherapy approved by the U.S. Food & Drug Administration (FDA) for the treatment of relapsed or refractory PTCL.
Please find information about FOLOTYN on this website, including efficacy, safety, dosing & administration, side effect management and the Allos patient support program ASAP.
Important Safety Information for FOLOTYN
Indications and Usage for ZEVALIN
ZEVALIN is a CD20-directed radiotherapeutic antibody administered as part of the ZEVALIN therapeutic regimen indicated for the treatment of patients with:
Important Safety Information for ZEVALIN
Indications and Usage for MARQIBO
MARQIBO is indicated for the treatment of adult patients with Philadelphia chromosome–negative (Ph–) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following 2 or more anti-leukemia therapies. This indication is based on overall response rate. Clinical benefit such as improvement in overall survival has not been verified.
Important Safety Information for MARQIBO
Indications and Usage for BELEODAQ
BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
Important Safety Information for BELEODAQ